Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with documented Physician's diagnosis of COPD, and currently receiving maintenance therapy.~* Aged \>=40 years of age at inclusion.~* Using one of the maintenance therapies of interest for at least 3 months prior to inclusion on the study.~* Males or females.~* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in the protocol.~Exclusion Criteria:~* Asthma: Subjects with a current diagnosis of asthma. Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD.~* Drug/alcohol abuse: Subjects with a known or suspected alcohol or drug abuse history at screening (Visit 0) that in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.~* Investigational product: Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening/Visit 1), or within five half-lives of the investigational drug, whichever is longer.~* Investigational product: Subjects who have been trained during participation in any device study in the 6 months prior to entry into this study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects using RELVAR ELLIPTA (Type: None): Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
- Subjects using SYMBICORT TURBUHALER (Type: None): Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
- Subjects using SERETIDE DISKUS (Type: None): Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
- Subjects using SPIRIVA HANDIHALER (Type: None): Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
- Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA (Type: None): Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
- Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER (Type: None): Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
- Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA (Type: None): Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
- Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA (Type: None): Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
- Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA (Type: None): Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.

Based on this trial design, predict the completion outcome and termination type (if applicable).